Europe authorizes Moderna's combined flu-COVID vaccine

Moderna's novel mRNA vaccine, designed to protect against both influenza and COVID-19 simultaneously, has received authorization in Europe. This marks a significant advancement in vaccine technology, offering a more convenient and potentially more effective approach to respiratory illness prevention. The vaccine's approval comes after Moderna withdrew its application to the U.S. Food and Drug Administration (FDA) last year, a decision reportedly influenced by external factors including anti-vaccine advocacy. This European endorsement could pave the way for broader adoption and further development of combination vaccines.